New research shows that measuring p-tau217 protein levels in blood plasma can predict when a person will begin showing Alzheimer's symptoms, potentially years before cognitive decline appears. A predictive model built from data on 603 older adults found that elevated p-tau217 tracks amyloid and tau buildup in the brain, and can estimate symptom onset within a margin of three to four years. Notably, age affects the timeline: younger individuals tolerate the pathology longer than older ones. The model code and a web-based exploration tool have been made publicly available. While not yet recommended for asymptomatic screening outside research, the approach could accelerate clinical trials for preventive drugs and help patients plan ahead.
Sort: